Efficacy and Tolerability of Cenobamate in Treating Refractory Focal Epilepsy: Results From the 6-month Open-label Cenobamate in Focal Epilepsy Study (CIFES)
These findings reinforce CNB as a valuable treatment option for patients with focal-onset drug-resistant epilepsy, supporting its integration into clinical practice. Further research is needed to evaluate long-term outcomes and its potential role as a first-line therapy.
Authors
- Tatiana Espinosa Oltra
- Juan Antonio García-Carmona
- María Ruíz-Perelló
- María López López
- Francisco Salazar Hernández
Institutions
- Santa Lucía University General Hospital (ES)
- Universidad Católica de Murcia (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- Clinical Neuropharmacology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1097/wnf.0000000000000673
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00